Previous studies have shown an increase in Cyp2b10 in mice with fatty liver [12] and the NAFLD inducer, perfluorooctanesulfonic acid, was shown to induce hepatocyte CYP2B6 activation in vitro [16], which is consistent with our conclusion. The gene discussed is CYP2B6; the disease is metabolic dysfunction-associated steatotic liver disease.